申请人:Merrell Dow Pharmaceuticals Inc.
公开号:US04650907A1
公开(公告)日:1987-03-17
Novel nonaromatic fluoroallylamines are potent MAO inhibitors and at low dose selectively inhibit MAO-B. They are useful in the treatment of depression and coadministered with L-dopa, in the treatment of Parkinsonism.
新型非芳香族氟丙烯胺是强效的MAO抑制剂,并且在低剂量下选择性地抑制MAO-B。它们在抑郁症治疗中非常有用,并可与L-多巴胺联合使用,用于帕金森病的治疗。